Source: Annual Congress 2003 - Newer and alternative non-steroidal treatments for asthmatic inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Chung, G. Kunkel, S. Ramos, G. Ayre, H. Fox, M. Blogg (London, Horsham, United Kingdom; Berlin, Germany; Oviedo, Spain). Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma. Eur Respir J 2003; 22: Suppl. 45, 1390

Member's Comments

No comment yet.

Related content which might interest you: Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001